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Earlier diagnosis and more effective treatments mean that the estimated number of cancer 112 
survivors in the UK is expected to reach 4 million by 2030. However, there is an increasing 113 
realisation that excess body fatness (EBF) is likely to influence the quality of cancer 114 
survivorship and disease-free survival. For decades, the discussion of weight management 115 
in patients with cancer has been dominated by concerns about unintentional weight loss, low 116 
body weight and interventions to increase weight, often re-enforced by the existence of the 117 
obesity paradox, which indicates that high body weight is associated with survival benefits 118 
for some types of cancer. However, observational evidence provides strong grounds for 119 
testing the hypothesis that interventions for promoting intentional loss of body fat and 120 
maintaining skeletal muscle in overweight and obese cancer survivors would bring important 121 
health benefits in terms of survival outcomes and long-term impact on treatment-related side 122 
effects. In this article, we outline the need for studies to improve our understanding of the 123 
health benefits of weight loss interventions, such as hypocaloric healthy eating plans 124 
combined with physical activity. In particular, complex intervention trials that are 125 
pragmatically designed are urgently needed to develop effective, clinically practical, 126 
evidence-based strategies for reducing EBF and optimising body composition in people 127 
living with and beyond common cancers.  128 
 129 
  130 









Improvements in the early detection and treatment of cancer have led to a dramatic increase 137 
in the number of cancer survivors — those people alive who have been diagnosed with 138 
cancer before, during and after treatment1. Globally, public health surveillance data show 139 
that 5‐year net survival rates from colon, rectal and breast cancers have increased steadily 140 
in the majority of developed countries,2 and, in the UK, the number of cancer survivors is 141 
expected to reach 4 million by 20303. The definition of survivors includes individuals who 142 
have been cured by treatments or who are on the road to recovery and aiming to reduce the 143 
risk of recurrence, as well as those living with metastatic disease, for whom efforts are more 144 
focussed on maximising treatment effectiveness, managing the side-effects of treatment and 145 
preserving quality of life.   146 
As we celebrate extended cancer survivorship, however, we must also be mindful of co-147 
morbid conditions4, including overweight and obesity characterised by excess body fatness 148 
(EBF), that can affect the quality of those additional years. Body mass index (BMI) is the 149 
measure most commonly used as a proxy for EBF; the measure becomes notable when the 150 
value increases beyond 25 kg/m2 (overweight) and is deemed substantial at levels above 151 
30kg/m2 (obesity). It is estimated that, worldwide, 1.9 billion adults and over 340 million 152 
children and adolescents are now living with overweight or obesity5. Although EBF has been 153 
identified as a risk factor for at least 13 different types of cancer6, its effect on cancer 154 
survivorship is less clear. However, the prevalence of EBF in Western societies means that 155 
its probable influence on the quality of cancer survivorship and the prospect of prolonged 156 
disease-free survival after primary curative treatment cannot be ignored.  The effects of EBF 157 
on insulin resistance, systemic inflammation and other circulating factors such as adipokines 158 
and sex hormones, which are linked to primary cancer risk, are well described6, and 159 
research into the biological mechanisms that underlie the obesity–cancer relationship (both 160 
in tumour initiation and progression) is ongoing7. EBF can influence the quantity, distribution 161 
and quality of adipose tissue, which is now recognised to comprise not just adipocytes, but 162 
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also blood vessel stromal cells and immune cells. Accordingly, the roles of adipose tissue 163 
have been found to extend beyond triacylglycerol storage to include (among many others) 164 
glucose and lipid metabolism, appetite regulation and, notably, immunity and inflammation, 165 
providing potential mechanisms by which EBF might influence cancer survivorship and 166 
response to treatment, as well as risk8,9. 167 
  168 
Several leading health authorities recommend the management of excess weight (e.g. 169 
avoiding weight gain, intentional weight loss and weight loss maintenance) for people living 170 
with and beyond cancer10,11,12   but service provision and resources for health behaviour 171 
change and the promotion of effective interventions within healthcare systems is 172 
suboptimal13. Weight management in cancer patients has routinely been dominated by 173 
concerns about unintentional weight loss (secondary to cancer treatments or due to 174 
progressive disease) and low body weight. These concerns have resulted in an emphasis on 175 
nutritional interventions to maintain or increase weight because of the negative outcomes 176 
associated with loss of body mass in people with advanced cancer. Nutrition screening tools 177 
focus on parameters of under-nutrition with little heed to the issues and adverse risk profile 178 
of patients who have EBF at diagnosis, or who gain further weight (body fat) during 179 
treatment and beyond.  180 
Consideration of the health benefits of managing EBF are largely overlooked. There is a 181 
perception that many clinicians fail to be convinced that interventions related to EBF are a 182 
key part of cancer care and will be beneficial to patient outcomes13. Clinicians might even 183 
avoid these issues because they are concerned about evoking feelings of guilt or 184 
undermining patient–health-professional relationships (especially where BMI is a known risk 185 
factor for the cancer site),13,14 despite opportunities (‘teachable moments’) to address this 186 
issue during and after cancer treatment. 187 
 188 
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The influence  of intentional weight loss on adipose tissue biology is unknown. It is possible 189 
that some effects of obesity might be imprinted, and therefore might not be reversible7. On 190 
the other hand, work in mouse models suggests that intentional weight loss through caloric 191 
restriction boosts anti-cancer immune surveillance and delays progression8.  It is also 192 
possible that these biological responses could enhance treatment outcomes and risk of 193 
disease recurrence. The importance of understanding more about the impact of obesity on 194 
both cancer incidence and outcomes was identified in 2020 as one of the eight research 195 
priority areas needed to accelerate progress in cancer management by the American 196 
Society for Clinical Oncology15. In this article, we outline the need for intervention trials to 197 
address the issue of whether promoting intentional loss of body fat and maintaining skeletal 198 
muscle in overweight and obese cancer survivors would bring important health benefits in 199 
terms of survival outcomes and long-term impact on treatment-related side effects. 200 
Realistically, management of excess body fatness is unlikely to become a core part of 201 
survivorship plans unless robust clinical trials and subsequent clinical guidelines can be 202 
developed. 203 
 204 
EBF and cancer survival 205 
Growing evidence from epidemiology studies indicates that avoiding EBF might have a role 206 
in reducing cancer morbidity and mortality worldwide. The Global Burden of Disease Study 207 
reported (using various ecological assumptions) in 2019 that amongst 896,040 colorectal 208 
cancer deaths occurring in 2017, 73,475 (8.2%) were attributable to a high BMI16. A meta-209 
analysis of 82 studies reported a 35% increase in breast-cancer-related mortality and a 41% 210 
increase in all-cause mortality in women with breast cancer who were obese, independent of 211 
menopausal status17. Similarly, meta-analyses suggest that obesity is associated with poorer 212 
survival outcomes in bladder,18 prostate,19 and hepatocellular20 cancer patients.  213 
 214 
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The obesity paradox  215 
Considerable debate surrounds the ‘obesity paradox’21,22, in which high body weight appears 216 
to be associated with survival benefits after diagnosis of colorectal,23 endometrial24 and lung 217 
cancer25. In some studies, this phenomenon can be explained by the association of obesity 218 
with less aggressive tumour subtypes, such as the increased incidence of type 1 tumours, 219 
which have a good prognosis, compared with type 2 tumours, which have poor prognosis, in 220 
obese endometrial cancer patients26.  A higher tolerance of some systemic anti-cancer 221 
therapies in overweight/ obese patients and the benefit of energy reserves to support the 222 
body during the stress of anti-cancer therapies have also been postulated as clinical 223 
explanations for the obesity paradox (Figure 1). In some cases, higher body weight might 224 
reflect greater fat fee mass which may increase the responsiveness to treatment regimens27 225 
However, in many publications, the association of enhanced survival with overweight or 226 
obese status is an artefact of methodological issues. These issues commonly include 227 
combining cohorts of patients with early and advanced cancer so that observational data are 228 
confounded by disease-related weight loss (reverse causality) and the use of heterogenous 229 
cohorts that fail to adjust for tumour biology, stage or treatment, or other confounders such 230 
as smoking. Other reported causes of the obesity paradox outlined in Figure 1 include 231 
detection bias, where patients undergoing medical investigation for obesity-related co-232 
morbidities are diagnosed with incidental early-stage cancers, and collider bias, a specific 233 
form of selection bias demonstrated in the relationships between smoking, cancer and 234 
obesity.  Cancer patients who are not obese might have other risk factors, such as smoking, 235 
and an inverse association is therefore artificially strengthened between obesity and cancer 236 
outcomes. Longer-term cohort studies that have the potential to provide better repeated 237 
measures over time are needed.  Finally, assessment of obesity by BMI fails to take body 238 
composition, notably body fat distribution, into account.  At the most basic measurement this 239 
would include markers of central obesity such as waist circumference. 240 
 241 
Weight gain after diagnosis and survival outcomes  242 
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Data regarding weight gain after diagnosis of common cancers add another layer of 243 
complexity to the link between EBF and cancer morbidity and mortality. For example, 244 
whereas poorer survival outcomes associated with weight gain are suggested for breast 245 
cancer after diagnosis28, current evidence for the influence of weight gain after diagnosis on 246 
colorectal cancer survival seems to be less clear-cut,29 notably when patients with early 247 
disease and those with metastatic disease (and high tumour burden) are included in the 248 
same analysis. Although some studies suggest that a higher BMI might be associated with 249 
better survival in patients with colorectal cancer, meta-analyses have reported little impact 250 
on the risk of survivorship in overweight patients, whereas both obese and underweight 251 
patients have an increased risk of all-cause mortality, cancer-specific mortality, disease 252 
recurrence and worse disease-free survival compared with patients of normal weight30. Being 253 
able to distinguish between intentional and unintentional weight loss is also important, as is 254 
the impact of weight loss on body composition — specifically, a reduction in EBF while 255 
maintaining lean body mass is desirable. In addition, certain treatment modalities are 256 
associated with weight gain, including endocrine therapy in breast and prostate cancer, and 257 
steroid treatments used as an adjunct to many chemotherapy regimens and as supportive 258 
care in many oncological emergencies associated with advanced cancer. These factors 259 
highlight the importance of investigating EBF and weight gain by treatment. Added to this, 260 
methodology concerns, including sampling selection bias, residual or unmeasured 261 
confounding factors, reverse causation and collider bias, call into question the 262 
epidemiological basis for the obesity paradox in this context. 263 
 264 
EBF, skeletal muscle mass, surrogate measures and survivorship   265 
A growing number of observational studies have relied on surrogate measures of adiposity 266 
(e.g. body weight, BMI, waist circumference), which do little to advance our understanding of 267 
how changes in the key body composition parameters of EBF and skeletal muscle mass 268 
might independently influence cancer survivorship.  Caan et al.31 argued that people who are 269 
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overweight or obese generally have higher levels of skeletal muscle than people of lower 270 
weight, thus decreasing the risk of disease recurrence, surgical complications and treatment-271 
related toxicities associated with lower skeletal muscle mass. It is, however, important to 272 
analyse appropriately for age when classifying sarcopenia32. When age is taken into 273 
consideration, sarcopenic obesity — skeletal muscle depletion despite high BMI — is 274 
reported to be prevalent in approximately one-tenth of patients with advanced solid tumours 275 
and is independently associated with increased complication and mortality rates across 276 
multiple cancer sites and treatment plans33. Furthermore, in non-metastatic breast cancer 277 
patients, computer-tomography-derived measures of sarcopenia and total adiposity at 278 
diagnosis were shown to be independently associated with overall mortality over six years of 279 
follow-up, whereas BMI was not34. These results further underline the need to assess body 280 
composition rather than rely on BMI in order to guide best advice for nutritional and physical 281 
activity survivorship plans.  282 
 283 
The effect of EBF on cancer treatment   284 
The effects of EBF and weight management interventions on treatment outcomes, post-285 
treatment morbidity and mortality might differ between cancer types, and many important 286 
research questions in this arena need to be answered35. For example, the impact of high BMI 287 
(reflecting EBF) on the efficacy of local and systemic cancer therapies and associated side 288 
effects in the context of optimising long-term treatment plans is largely understudied36. A 289 
systematic review of the effect of obesity on toxicity in women treated with chemotherapy in 290 
early stage breast cancer concluded that obese patients tolerate chemotherapy better than 291 
lean patients37. However, it was acknowledged by the authors  that this observation “may be 292 
confounded by poorly specified dose-capping practices and the use of haematopoietic growth 293 
factors” (which may have been used more frequently in obese patients if clinicians perceived 294 
that these patients were at a higher risk of myelosuppression due to higher absolute drug 295 
doses). 296 
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A narrative review34 evaluating the effect of obesity on a wide variety of oncology treatment 297 
modalities highlighted a number of points. First, technical challenges posed by high BMI 298 
might adversely impact surgical morbidity outcomes (e.g. increased risk of surgical site 299 
infections, reduced lymph node harvest and increased risk of margin positivity). Second, the 300 
potential exists for suboptimal chemotherapy dosing; this is associated with capping 301 
chemotherapy in obese patients to avoid toxicity and might be a driver of poor prognostic 302 
outcomes. Conversely, however, the efficacy of immune checkpoint inhibition could 303 
potentially be enhanced in patients who are obese . These checkpoints moderate the 304 
immune response and the ability to impact on tumour cells. Immunotherapy agents have 305 
been developed for a number of cancers and the importance of these in the overweight and 306 
obese is emerging.34 307 
 308 
The review also raised an important question: does EBF influence outcomes directly through 309 
cancer biology (such as via the effects of adipose tissue on the levels of oestrogens, insulin, 310 
insulin-like growth factors and other adipokines to create a pro-inflammatory environment 311 
that encourages carcinogenesis) or are the adverse outcomes of EBF mediated through 312 
indirect pathways (e.g. chemotherapy dosing) that result in suboptimal treatment?  313 
 314 
Interpreting the results of observational studies investigating the effect of EBF on 315 
mortality and survival  316 
Various studies have investigated the impact of EBF on a range of cancer outcomes in many 317 
cancer types but, to date, the evidence on overall survivorship risks is inconclusive. In 318 
summarising these studies (for example, in breast cancer), the World Cancer Research Fund 319 
(WCRF) Continuous Update Project (CUP) panel10 developed a framework for interpreting the 320 
effect of anthropometric measures on mortality and survival at three key time-points: pre-321 
diagnosis of cancer; peri-diagnosis/peri-treatment; and during survivorship (see Table 1). 322 
Exposures (diet, physical activity, body composition) measured prior to cancer diagnosis are 323 
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anticipated to influence cancer incidence and overall mortality via an effect on cancer biology.   324 
The main biological mechanisms of interest (metabolic regulators including insulin, insulin-like 325 
growth factor 1, adipokines, inflammation-related molecules, and steroid hormones, as well 326 
as the cellular and structural components of the tumour microenvironment, including adipose 327 
tissue)38 are likely to have long-term impacts without appropriate interventions. 328 
Interventions based on these exposures are thus relevant to cancer prevention strategies 329 
but further evidence will be required for weight management policies in cancer survivors. 330 
Anthropometric measurements taken at the time of cancer diagnosis can be assessed as 331 
prognostic indicators but must be interpreted in the context of the cancer type, stage and 332 
patient performance status, as well as the timing of measurements in relation to treatment 333 
modalities. The impact of body composition on therapy-related toxicities is equally important 334 
in patients with advanced cancer where the goals of systemic therapies are to improve and 335 
maintain quality of life whilst also extending life expectancy. This area is poorly addressed in 336 
the current literature and represents an important unmet research need. However, as recent 337 
weight loss is a frequent presentation of advanced stage cancer (reverse causality), there is 338 
a need to analyse the association of body mass and survival in advanced stage patients 339 
separately to that of patients with early stage disease who are less likely to present with 340 
weight loss and will have a longer median survival time. 341 
Assessment of body mass and size after treatment also needs attention in relation to the 342 
type of treatment received for different tumour types and any associated toxicities, and an 343 
awareness of selection against patients with rapid disease progression who have not 344 
survived to this point.  345 
 346 
Weight loss trials: a gap in the evidence  347 
Despite the limitations of observational data, the consistency and magnitude of associations 348 
between EBF/weight gain and survival outcomes for some cancers reported in systematic 349 
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reviews and meta-analyses support the need for intervention studies27,39. To date, weight 350 
loss intervention studies have predominantly been carried out in breast cancer survivors.  A 351 
large-scale dietary intervention trial (low fat, high fruits and vegetables) in women with early-352 
stage breast cancer — the Women’s Intervention Nutrition Study (WINS) — was successful 353 
in supporting women to lose weight, with indications of lower cancer recurrence in the 354 
intervention group, notably in women with oestrogen-receptor (ER)-negative disease40. 355 
Furthermore, a growing number of short-term trials have demonstrated the effects of 356 
intentional weight loss on blood-borne biomarkers of cancer and cardiometabolic risk, 357 
including changes in serum sex hormones,41 inflammation markers42 and insulin sensitivity43. 358 
A small number of ongoing intentional weight loss trials are also ongoing in breast cancer 359 
survivors44,45,46 and are expected to report on survival and associated outcomes over the 360 
next decade.  Weight loss trials have also been undertaken in endometrial cancer 361 
survivors47. However, a 2018 Cochrane review48 concluded that there is insufficient high-362 
quality evidence to determine the effect of interventions on survival, quality of life or 363 
cardiovascular events. The authors highlighted problems of high risk of bias by failing to 364 
blind personnel and outcome assessors, and significant losses to follow-up. They also 365 
emphasised the need for adequately powered trials with a follow-up of at least 5–10 years 366 
duration.  367 
Importantly, no trial has yet established the effect of intentional weight loss following a 368 
cancer diagnosis on mortality and many gaps in our understanding of how to optimise such 369 
interventions remain. The optimal contributions of diet composition, caloric intake, amount 370 
and nature of physical activity (including sedentary time) for promoting loss of EBF and 371 
avoiding weight gain49 are important considerations for future intervention research. 372 
Furthermore, the effects of weight management interventions on treatment-related side 373 
effects, as well as bone health, physical function, psychosocial issues and quality of life, 374 
have not been clearly defined for many cancers and intervention studies are needed to 375 
address these important issues48. 376 
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Weight management strategies in overweight and obese cancer survivors might also have a 377 
role to play in the prevention of non-cancer deaths — for some individual patients, the 378 
presence of EBF might also confer a poorer prognosis for survival from non-cancer disease. 379 
For example, cancer patients who also have diabetes have a decreased overall survival 380 
compared with cancer patients without diabetes, in part because they are at increased risk of 381 
non-cancer (mainly cardiovascular) deaths,50 which might be further increased by certain 382 
treatments (e.g. anthracycline chemotherapy).  383 
Whilst the case for examining the impact of weight management can be made from current 384 
evidence, the design of programmes to capture the magnitude of effect and possible 385 
negative consequences need to be fully explored. 386 
 387 
Time to invest in intervention research for EBF? 388 
Developing and testing interventions for promoting the intentional loss of EBF and 389 
maintaining skeletal muscle mass require a number of considerations, which we outline 390 
below.   391 
 392 
Optimum timing of interventions  393 
The optimum window for weight loss interventions in cancer survivors needs careful 394 
consideration. Treatment for cancer is increasingly being delivered over longer periods of 395 
time and is multi-modal in nature; acute side effects, including unintentional gains in body 396 
weight and changes in body composition, which might negatively influence cancer outcomes 397 
and response to treatment, are not uncommon51. Of early-stage breast cancer patients 398 
receiving chemotherapy, 30–60% gain significant weight. This weight gain involves losing 399 
skeletal muscle while gaining adiposity52  and adversely impacts quality of life and overall 400 
health53. Young breast cancer patients can gain over 5% body weight in the first 12 months 401 
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after diagnosis54, which is associated with changes in eating habits resulting from emotional 402 
stress as well as the side effects of treatments (e.g. steroids and chemotherapy-induced 403 
menopause, cancer-related fatigue and reduced physical activity). Clearly, interventions that 404 
provide the support needed to help patients avoid or limit unintentional weight gain during 405 
treatment and/or facilitate EBF loss following completion of treatment whilst maintaining 406 
adequate levels of physical activity would be valuable adjuncts to curative cancer care 407 
pathways. 408 
Changes in nutritional and metabolic status that influence sarcopenia and cachexia must be 409 
addressed with the appropriate nutritional support throughout treatment11 irrespective of 410 
body weight. For this reason, intentional weight loss interventions might be challenging and 411 
possibly inadvisable for some cancer populations during the period of treatment, and the 412 
post-treatment period is likely to offer a more practical time frame. For example, 413 
chemoradiation treatment for patients with head and neck cancers is already associated with 414 
a significant incidence of weight loss and malnutrition, and patients frequently require 415 
nutritional support during treatment, while patients with upper gastrointestinal cancer often 416 
present with rapid weight loss owing to dysphagia and, again, management should be 417 
focussed on optimising nutritional intake prior to and during treatment. 418 
 419 
The study population  420 
Careful consideration needs to be given to the study population, including age, location, 421 
ethnicity, co-morbidities, primary cancer site and stage of disease when designing weight 422 
loss interventions aimed at optimising efficacy and effectiveness. Trials to investigate the 423 
benefits of intentional weight loss are most likely to be acceptable to clinicians and patients 424 
in cancer populations where there is evidence that EBF is associated with second cancer 425 
risk or poorer outcome. In addition, low frequency of rapid weight loss at presentation or 426 
associated with common first-line treatment strategies will also make intentional weight loss 427 
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programmes seem more appropriate. Patients with early-stage presentations of breast, 428 
endometrial, colorectal and prostate cancers might meet these requirements. Close attention 429 
must also be paid to the biology of the disease, particularly within metastatic cancer 430 
populations: patients with ER-positive metastatic breast cancer and no visceral disease 431 
frequently have an indolent disease course that can be managed predominantly by 432 
endocrine therapy over many years and constitute, potentially, a more appropriate 433 
population for weight intervention strategies than patients with triple-negative metastatic 434 
disease who frequently develop rapid disease progression leading to failure of vital organs. 435 
 436 
Outcome measures 437 
Outcome measures in weight management trials should include those that are patient-438 
reported as well as clinically reported. Patient-reported outcomes (PROMS) include 439 
measures of quality of life, which can be broadly categorised into five groups: general health 440 
and well-being; physical factors (e.g. weight loss); symptoms (e.g. pain, nausea, fatigue); 441 
psychological factors (e.g. anxiety, insomnia, self-esteem); and social factors (e.g. 442 
relationships and work). Clinical outcome measures might vary according to cancer site and 443 
treatment regimens, but should include those assessing acute and long-term side effects of 444 
local and systemic therapies (e.g. lymphoedema volumes, fatigue scores, bone mineral 445 
density, cardiac ejection fractions, etc.) as well as cancer outcomes (locoregional and distant 446 
disease-free survival) and overall survival. Circulating biomarkers and surrogate endpoints 447 
(e.g. adenomas, breast density,55 etc.) should be used alongside PROMS to gain an 448 
overview of relevant biological and well-being perspectives allowing clinical, scientific and 449 
person-specific characteristics insights to the impact of interventions.   450 
 451 
Minimising heterogeneity/standardising outcomes 452 
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Sources of heterogeneity need to be carefully considered and controlled for in the design of 453 
weight management studies and/or considered during the analytic phase. The potential for 454 
clinical heterogeneity in outcomes exists according to disease subtype, stage and grade, as 455 
well as in the treatment received, but methodological heterogeneity in the way outcomes are 456 
defined can also occur. It is plausible that patients with different cancers might respond 457 
differently to weight management interventions — notably, those with obesity-related 458 
cancers versus non-obesity-related cancers. Standardising outcomes is important for 459 
consistency and for comparison across trials and allows incorporation into meaningful meta-460 
analyses. To improve the definition and measurement of outcomes, the Core Outcome 461 
Measures in Effectiveness Trials (COMET) initiative56 provides guidance for researchers by 462 
advocating a standardised set of outcomes that should be measured and reported, as a 463 
minimum, in all clinical trials of health, including weight management. Examples listed in 464 
Table 2 illustrate the breadth of outcomes, similarities and differences by site used by 465 
different research teams and highlights the need for further work on agreed core 466 
outcomes.  Additionally, incorporation of the accumulating data to optimally predict obesity 467 
treatment (ADOPT)57 biological domain framework could advance the understanding of 468 
individual variability in response to adult obesity treatments and explore the physiological 469 
mechanisms that could influence cancer recurrence. 470 
 471 
Weight management intervention design 472 
The design of weight management intervention (in terms of dose and duration) needs to be 473 
driven by practicalities as well as the desired magnitude of change in body composition (e.g. 474 
body fatness and skeletal muscle mass) — this approach has the greatest likelihood of 475 
positively influencing patient and clinical outcomes58. Caloric intake is the cornerstone of 476 
weight loss, but regular physical activity and structured exercise programmes have important 477 
roles to play in all aspects of weight management59.  Importantly, physical activity and 478 
exercise can preserve skeletal muscle mass during dietary-induced fat loss60,61, thereby 479 
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helping to protect against the adverse impact of sarcopenia on cancer survival outcomes31,62  480 
and increasing total daily energy output63.  Physical activity post-diagnosis is associated with 481 
improved survival outcomes for patients with breast, colorectal or prostate cancer 64. 482 
Furthermore, an international consensus statement concluded that sufficient evidence now 483 
exists to show that regular exercise improves several cancer-related health outcomes, 484 
including anxiety, depressive symptoms, fatigue, physical functioning and health-related 485 
quality of life in cancer survivors65. 486 
  487 
The growing body of effective weight loss programmes (BRRIDE;66, DIRECT;67 ,DPP68), that 488 
have achieved clinically relevant changes (e.g. diabetes remission) in cancer and non-489 
cancer patients provides a good starting point for intervention design. However, translating 490 
these programmes into cancer survivorship populations might require significant patient 491 
involvement to ensure that the components (notably, dietary and structured exercise or 492 
physical activity goals) can be achieved by those with a wide range of abilities, disabilities, 493 
emotional needs, available time and financial circumstances.  Furthermore, insights from 494 
behavioural science69 provide guidance for embedding strategies to support long-term 495 
behavioural change, which are anchored in robust psychological theory and evidence-based 496 
behaviour change techniques. The potential of remote support offered by digital and other 497 
‘smart’ technologies (in particular, to people with co-morbid conditions such as cognitive and 498 
sight impairments) provides further scope to engage with vulnerable people, including those 499 
living in rural communities. 500 
Feasibility studies  501 
Finally, feasibility trials are an essential starting point for definitive randomised controlled 502 
trials with respect to gauging patient acceptability and tolerability, and gleaning valuable 503 
qualitative and quantitative data about recruitment, implementation, retention and indicative 504 
effects. One novel method that could transform the interpretation of feasibility trials is the use 505 
Cancer survivorship and excess body fatness – where are we in 2020? 
20 
 
of Mendelian randomisation. In this context, feasibility studies can estimate the intervention 506 
effects on intermediate endpoints that might be on the causal pathway to clinical outcomes. 507 
Using a two-step process, the results of small-scale feasibility studies can be used to inform 508 
much larger-scale two-sample Mendelian randomisation studies. This approach could 509 
provide novel insight into the causal effects of an intervention on important intermediate 510 
endpoints and possible long-term clinical endpoints (see Figure 2). In this way, Mendelian 511 
randomisation can then be used alongside feasibility studies to optimise intervention 512 
development and delivery, including more accurate outcome predictions for fully powered 513 
conventional randomised controlled trials,70 as outlined in Figure 271. 514 
 515 
Conclusions  516 
It is timely to extend our knowledge of weight management by moving from epidemiology 517 
studies to interventional research, as it relates to EBF in the context of cancer treatment and 518 
survivorship.  This increased knowledge will improve our understanding of the health 519 
benefits to be gained from optimising body composition in people living with and beyond 520 
common cancers, who constitute a significant health burden worldwide. Interventions need 521 
to be complex but pragmatic in design, while encompassing multi-disciplinary 522 
methodological approaches aimed at improving our understanding of causal mechanisms.  523 
These endeavours are urgently needed to develop evidence-based strategies for mitigating 524 
the adverse impact of EBF in a growing global population of cancer survivors67 living in 525 
increasingly obesogenic societies.  526 
 527 
Additional Information 528 
Table 1: Interpretation of studies evaluating anthropometric measures on mortality and 529 
survival 530 
Table 2: Range of core outcomes relevant in clinical trials of weight management 531 
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Figure 1: Possible explanations for the obesity paradox 532 
Figure 2: Two-step Mendelian Randomisation procedure: Integration of feasibility 533 
randomised controlled trial (RCT) results with MR to predict long-term effect of interventions   534 
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Legends 
Table 1: Interpretation of studies evaluating anthropometric measures on mortality and 
survival 
Table 2: Range of core outcomes relevant in clinical trials of weight management 
Figure 1: Despite significant evidence that excess body fat (EBF) is associated with reduced 
cancer survival, data from a number of studies indicate that overweight and early obese 
cancer patients exhibit improved survival — this is known as the so-called ‘obesity paradox’.  
Although there are potential clinical and biological explanations for this in specific patient 
groups (red circles), many of these reports can be explained by methodological mechanisms 
(blue circles), including the inadequacy of BMI as a measure of adiposity   
Figure 2: Introduction to Mendelian randomisation: Mendelian randomisation is a form of 
instrumental variable analysis that uses genetic variants as instruments to examine the 
causal effects of modifiable exposures on outcomes of interest. This method depends on the 
existence of genetic variants that are robustly associated with metabolite levels.    
In the example outlined here, the results of a feasibility RCT of dietary interventions for the 
prevention of prostate cancer were carried forward to a large-scale Mendelian randomisation 
analysis to infer the causal effect of the interventions on prostate cancer risk via intermediate 
metabolites.  
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Step 1 assessed the randomised effects of lycopene and green tea consumption for 6 
months versus placebo on 159 serum metabolic traits, quantified by Nuclear Magnetic 
Resonance (NMR), amongst 133 men enrolled in the ProDiet randomised controlled trial     
Step 2 used Mendelian randomisation to assess the effects of those metabolic traits altered 
by the intervention on prostate cancer risk, using genome-wide association studies (GWAS) 
summary statistics from the Prostate Cancer Association Group to Investigate Cancer 
Associated Alterations in the Genome (PRACTICAL) consortium. The lycopene intervention 
lowered circulating levels of pyruvate, a change that the Mendelian randomisation analysis 
suggested was associated with decreases in prostate cancer risk (a genetically instrumented 
SD increase in pyruvate increased the odds of prostate cancer by 1.29 (1.03, 1.62; p = 
0.027)). Lycopene lowered levels of pyruvate, which our Mendelian randomisation analysis 
suggests may be causally related to reduced prostate cancer risk. By combining the results 
of a feasibility study with Mendelian randomisation, it has been possible to identify potential 
intermediate mechanisms through which interventions might be influencing cancer risk (see 
767,68 (step 2). 
 
 
